Best response to selinexor by dose and NHL and DLBCL subtype
| Population . | No. of evaluable patients . | No. (%) . | |||||
|---|---|---|---|---|---|---|---|
| CR . | PR . | SD . | PD . | OR rate . | DCR . | ||
| Selinexor dose range, mg/m2 | |||||||
| All | 70 | 4 (6) | 18 (26) | 21 (30) | 28 (40) | 22 (31) | 43 (61) |
| 3-23 (median, 20) | 13 | 1 (8) | 3 (23) | 6 (46) | 3 (23) | 4 (31) | 10 (77) |
| 30-35 (median, 35) | 28 | 3 (11) | 8 (29) | 10 (36) | 7 (25) | 11 (39) | 21 (75) |
| 40-80 (median, 60) | 29 | — | 7 (24) | 5 (17) | 17 (59) | 7 (24) | 12 (41) |
| NHL subtype | |||||||
| DLBCL* | 41 | 4 (10) | 9 (22) | 8 (20) | 20 (49) | 13 (32) | 21 (51) |
| FL | 8 | — | 2 (25) | 6 (75) | — | 2 (25) | 8 (100) |
| CLL | 6 | — | 2 (33) | 3 (50) | 1 (17) | 2 (33) | 5 (83) |
| Richter’s transformation | 5 | — | 2 (40) | 2 (40) | 1 (20) | 2 (40) | 4 (80) |
| MCL | 3 | — | 1 (33) | 1 (33) | 1 (33) | 1 (33) | 2 (66) |
| CTCL | 3 | — | 1 (33) | 1 (33) | 1 (33) | 1 (33) | 2 (66) |
| PTCL | 2 | — | 1 (50) | — | 1 (50) | 1 (50) | 1 (50) |
| MZL | 1 | — | — | — | 1 (100) | — | — |
| Burkitt’s | 1 | — | — | — | 1 (100) | — | — |
| DLBCL subtype | |||||||
| De novo | 28 | 3 (11) | 3 (11) | 6 (29) | 16 (50) | 6 (21) | 12 (43) |
| Transformed FL | 12 | 1 (8) | 5 (42) | 2 (17) | 4 (33) | 4 (33) | 6 (50) |
| GCB | 20 | 3 (15) | 4 (20) | 5 (25) | 8 (40) | 7 (35) | 12 (60) |
| Non-GCB | 5 | 1 (20) | — | 1 (20) | 3 (60) | 1 (20) | 2 (40) |
| Double or triple hit | |||||||
| MYC/BCL2 | 5 | 1 (20) | 2 (40) | — | 2 (40) | 3 (60) | 3 (60) |
| MYC/BCL2/BCL6 | 1 | — | — | — | 1 (100) | — | — |
| Population . | No. of evaluable patients . | No. (%) . | |||||
|---|---|---|---|---|---|---|---|
| CR . | PR . | SD . | PD . | OR rate . | DCR . | ||
| Selinexor dose range, mg/m2 | |||||||
| All | 70 | 4 (6) | 18 (26) | 21 (30) | 28 (40) | 22 (31) | 43 (61) |
| 3-23 (median, 20) | 13 | 1 (8) | 3 (23) | 6 (46) | 3 (23) | 4 (31) | 10 (77) |
| 30-35 (median, 35) | 28 | 3 (11) | 8 (29) | 10 (36) | 7 (25) | 11 (39) | 21 (75) |
| 40-80 (median, 60) | 29 | — | 7 (24) | 5 (17) | 17 (59) | 7 (24) | 12 (41) |
| NHL subtype | |||||||
| DLBCL* | 41 | 4 (10) | 9 (22) | 8 (20) | 20 (49) | 13 (32) | 21 (51) |
| FL | 8 | — | 2 (25) | 6 (75) | — | 2 (25) | 8 (100) |
| CLL | 6 | — | 2 (33) | 3 (50) | 1 (17) | 2 (33) | 5 (83) |
| Richter’s transformation | 5 | — | 2 (40) | 2 (40) | 1 (20) | 2 (40) | 4 (80) |
| MCL | 3 | — | 1 (33) | 1 (33) | 1 (33) | 1 (33) | 2 (66) |
| CTCL | 3 | — | 1 (33) | 1 (33) | 1 (33) | 1 (33) | 2 (66) |
| PTCL | 2 | — | 1 (50) | — | 1 (50) | 1 (50) | 1 (50) |
| MZL | 1 | — | — | — | 1 (100) | — | — |
| Burkitt’s | 1 | — | — | — | 1 (100) | — | — |
| DLBCL subtype | |||||||
| De novo | 28 | 3 (11) | 3 (11) | 6 (29) | 16 (50) | 6 (21) | 12 (43) |
| Transformed FL | 12 | 1 (8) | 5 (42) | 2 (17) | 4 (33) | 4 (33) | 6 (50) |
| GCB | 20 | 3 (15) | 4 (20) | 5 (25) | 8 (40) | 7 (35) | 12 (60) |
| Non-GCB | 5 | 1 (20) | — | 1 (20) | 3 (60) | 1 (20) | 2 (40) |
| Double or triple hit | |||||||
| MYC/BCL2 | 5 | 1 (20) | 2 (40) | — | 2 (40) | 3 (60) | 3 (60) |
| MYC/BCL2/BCL6 | 1 | — | — | — | 1 (100) | — | — |
Nine patients were nonevaluable for response (3 had Richter’s transformation; 2 DLBCL; 1 CLL; 1 FL; 1 mantle cell lymphoma [MCL]; and 1 peripheral T-cell lymphoma [PTCL]).
CTCL, cutaneous T-cell lymphoma; DCR, disease control rate; MZL, marginal zone lymphoma; PD, progressive disease.
Includes 1 FL grade 3b.